MedTrace Logo

Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.

NCT04564742 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4017

Last updated 2025-03-07

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF), cardiovascular (CV) death, and other cardiometabolic outcomes.

Conditions

Interventions

DRUG

Dapagliflozin

Dapagliflozin 10 mg tablets given once daily, per oral use

DRUG

Placebo

Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use

Sponsors & Collaborators

  • Uppsala University

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Stefan James · Uppsala University

  • Jonas Oldgren · Uppsala University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-22
Primary Completion
2023-07-05
Completion
2023-07-05
FDA Drug
Yes

Countries

  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04564742 on ClinicalTrials.gov